| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IGFLR1 |
| Uniprot No | Q9H665 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-163aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSSQYCGRLEYWNPDNKCCSSCLQRFGPP PCPDYEFRENCGLNDHGDFVTPPFRKCSSGQCNPDGAELCSPCGGGAVTP TPAAGGGRTPWRCRERPVPAKGHCPLTPGNPGAPSSQERSSPASSIAWRT PEPVPQQAWPNFLP |
| 预测分子量 | 18 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是模拟的关于IGFLR1重组蛋白的参考文献示例(实际文献需通过学术数据库验证)：
---
1. **文献名称**: *Cloning and Functional Characterization of Recombinant IGFLR1 in Cancer Cell Signaling*
**作者**: Zhang L, et al.
**摘要**: 本研究成功克隆并表达了人源IGFLR1重组蛋白，通过体外实验证实其参与调控MAPK/ERK信号通路，并促进特定癌细胞的迁移和侵袭。
2. **文献名称**: *Structural Analysis of IGFLR1-Ligand Interaction Using Recombinant Protein*
**作者**: Kim S, et al.
**摘要**: 利用重组IGFLR1蛋白进行晶体结构解析，揭示了其与配体IGFL2的结合位点，为靶向药物设计提供了结构基础。
3. **文献名称**: *Recombinant IGFLR1 Protein Attenuates Inflammation in Murine Models*
**作者**: Patel R, et al.
**摘要**: 在小鼠模型中，重组IGFLR1蛋白通过抑制NF-κB通路显著减轻炎症反应，提示其潜在治疗慢性炎症性疾病的应用价值。
4. **文献名称**: *Expression Optimization of IGFLR1 in Mammalian Cells for Therapeutic Screening*
**作者**: Müller J, et al.
**摘要**: 报道了哺乳动物细胞系统中高效表达重组IGFLR1的优化策略，并验证其在高通量药物筛选中的稳定性与活性。
---
**注意**：以上内容为示例性模拟，IGFLR1相关研究较为前沿且可能命名存在差异，建议通过PubMed、Google Scholar等平台结合关键词“IGFLR1 recombinant”“IGFL receptor 1”进一步检索核实。
IGFLR1 (Insulin-like Growth Factor-like Receptor 1) is a transmembrane protein belonging to the immunoglobulin superfamily, initially identified through homology searches for receptors structurally related to the insulin-like growth factor (IGF) and insulin receptor families. Unlike classical IGF receptors, IGFLR1 lacks intrinsic tyrosine kinase activity but interacts with intracellular adaptor proteins to mediate downstream signaling. It is primarily recognized for binding members of the IGFL family (IGFL1-4), secreted proteins sharing partial homology with IGFs but exhibiting distinct expression patterns and regulatory roles.
The IGFLR1-IGFL axis is implicated in tissue development, epidermal differentiation, and immune modulation. Studies suggest its involvement in skin homeostasis, where it regulates keratinocyte proliferation and wound healing. In cancer biology, IGFLR1 overexpression has been observed in certain tumors, potentially influencing cell migration and survival through cross-talk with pathways like MAPK/ERK and PI3K/AKT. However, its precise mechanistic roles remain under investigation, partly due to overlapping functions with other IGF system components.
Recombinant IGFLR1 proteins are typically produced in mammalian expression systems to ensure proper post-translational modifications. These proteins serve as critical tools for ligand-receptor interaction studies, structural analyses, and screening therapeutic agents targeting IGFLR1-associated diseases. Recent interest in IGFLR1 stems from its potential as a biomarker in inflammatory skin disorders and its emerging role in metabolic regulation, though functional redundancy within the IGF/insulin receptor network complicates definitive pathophysiological assignments. Current research focuses on delineating its tissue-specific signaling outputs and therapeutic relevance in oncology and dermatology.
×
